, May 21, 2014
/PRNewswire/ -- Curemark
, a leading drug research and development company focused on the treatment of neurological and other diseases, announced today that the company was named a Red Herring Top 100 North American award-winner.
"We believe that Curemark embodies the vision, drive, and innovation that define a successful entrepreneurial venture. Curemark should be proud of its accomplishment as the competition was very strong," stated Alex Vieux, published and CEO of Red Herring.
The Red Herring Top 100 recognizes cutting edge private technology companies from the North American business region which are positioned for significant growth. Previous winners include Google, Facebook, Yahoo, Skype, Linkedin, Zynga, YouTube and eBay. The selection criteria include strength of management, financing history, intellectual property, and the size of the company's market.
"We are extremely excited by this level of recognition," said Dr. Joan Fallon, founder and CEO of Curemark. "We continue to move forward toward achieving approval of the first novel drug for the treatment of autism."
Curemark previously announced that it has begun the rolling submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for CM-AT, the company's autism treatment. The FDA has granted CM-AT the agency's Fast Track designation. The Fast Track designation is provided to investigational new drugs that are intended to treat serious or life-threatening conditions and that have demonstrated the potential to meet unmet medical needs.
About Curemark LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about the company's innovative science, visit www.curemark.com
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark LLC